The drug, ivonescimab, produced weaker results in patients from North America and Europe than those from China.
Summit Therapeutics may have a geography problem with its lung cancer drug ivonescimab.
In a study update reported Sunday, patients from North America and Europe treated with the drug saw their lung cancer return and progress faster than patients fro... [435 chars]